LGALS3 and glioblastoma: Label-free LC-MS/MS quantitative proteomic analysis of control and iOGA groups (O-GlcNAcylation dynamics disrupted with OGA inhibitor Thiamet G) identified altered Gal-3 expression in glioblastoma (GBM) secretome, predicting Gal-3 could be a substrate for O-GlcNAc addition and removal [121].